Suchergebnisse - "Navani, Vishal"

PubPharm (29)

1

Progression-Free Survival Gain : A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Stewart, D. | Ramsay, T. | Navani, V. | +3

2

Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database

enthalten in: Cancer | 2024

von Guram, K. | Huang, J. | Mouchati, C. | +18

3

Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

enthalten in: JAMA network open | 2024

von Cook, S. | Samuel, V. | Meyers, D. | +8

4

Immunotherapy in renal cell carcinoma

enthalten in: The Lancet. Oncology | 2023

von Navani, V. | Heng, D.

5

Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy : Results from the International Metastatic Renal Cell Carcinoma Database Consortium

enthalten in: European urology oncology | 2023

von Takemura, K. | Ernst, M. | Navani, V. | +17

6

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors

enthalten in: The oncologist | 2023

von Stukalin, I. | Navani, V. | Gupta, M. | +13

7

Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma

enthalten in: European urology | 2023

von Ernst, M. | Navani, V. | Wells, J. | +17

ErratumIn: Eur Urol. 2023 Jun;83(6):e166-e167. - PMID 36967358

8

Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023

enthalten in: European urology | 2023

von Ernst, M. | Navani, V. | Wells, J. | +17

ErratumFor: Eur Urol. 2023 Jan 25;:. - PMID 36707357

9

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma

enthalten in: JAMA network open | 2023

von Gupta, M. | Stukalin, I. | Meyers, D. | +5

10

Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade

enthalten in: Clinical lung cancer | 2023

von Navani, V. | Meyers, D. | Ruan, Y. | +11